{"id":1030564,"date":"2011-06-19T15:56:58","date_gmt":"2011-06-19T15:56:58","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/human-reproduction\/spermatogenetic-inhibition-in-men-taking-a-combination-of-oral-medroxyprogesterone-acetate-and-percutaneous-testosterone-as-a-male-contraceptive-method.php"},"modified":"2024-08-17T14:59:05","modified_gmt":"2024-08-17T18:59:05","slug":"spermatogenetic-inhibition-in-men-taking-a-combination-of-oral-medroxyprogesterone-acetate-and-percutaneous-testosterone-as-a-male-contraceptive-method","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-reproduction\/spermatogenetic-inhibition-in-men-taking-a-combination-of-oral-medroxyprogesterone-acetate-and-percutaneous-testosterone-as-a-male-contraceptive-method.php","title":{"rendered":"Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method"},"content":{"rendered":"<p>BACKGROUND<\/p>\n<p>We previously demonstrated in a small pilot study that oral medroxyprogesterone acetate and percutaneous testosterone (OMP\/PT) induce reversible spermatogenesis suppression. The aims of this study were to determine the rate of spermatogenetic inhibition and recovery and to obtain preliminary data on efficacy for a larger population under OMP\/PT.<\/p>\n<p>METHODS<\/p>\n<p>A total of 35 healthy men with normal spermiograms requesting male hormonal contraception were treated with OMP (20 mg\/day) and PT (50&ndash;125 mg\/day) for periods up to 18 months. Couples were included in a contraceptive efficacy phase after a value of &le;1 million\/ml spermatozoa was reached between 1 and 3 months of treatment.<\/p>\n<p>RESULTS<\/p>\n<p>Sperm counts decreased by 47% at 1 month, reaching 90% at 2 months and 98&ndash;100% between 4 and 8 months. At 3 months, 80% of men had &le;1 million\/ml spermatozoa. Follicle-stimulating hormone and luteinizing hormone decreased to 35% of pretreatment levels after 1 month of treatment and to 75&ndash;80% at 2 and 6 months, respectively. Plasma testosterone and estradiol levels were in the eugonadal range at 3, 6, 9 and 12 months of treatment. Dihydrotestosterone concentrations were 2&ndash;4 times higher than pretreatment values. The rate of spermatogenetic recovery was rapid (73 &plusmn; 29.5 days). During the efficacy phase (211 months for 25 couples), one pregnancy attributable to poor compliance of the male partner was observed.<\/p>\n<p>CONCLUSIONS<\/p>\n<p>OMP\/PT efficiently inhibits spermatogenesis in 80% of men, maintains testosterone at physiological levels and avoids the need for parenteral administration, which is poorly accepted by French men. These results justify larger studies to define a more adequate dosage of OMP\/PT and to confirm its efficacy and safety.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BACKGROUND We previously demonstrated in a small pilot study that oral medroxyprogesterone acetate and percutaneous testosterone (OMP\/PT) induce reversible spermatogenesis suppression. The aims of this study were to determine the rate of spermatogenetic inhibition and recovery and to obtain preliminary &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-reproduction\/spermatogenetic-inhibition-in-men-taking-a-combination-of-oral-medroxyprogesterone-acetate-and-percutaneous-testosterone-as-a-male-contraceptive-method.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246857],"tags":[],"class_list":["post-1030564","post","type-post","status-publish","format-standard","hentry","category-human-reproduction"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1030564"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1030564"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1030564\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1030564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1030564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1030564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}